Login Register Cart 0
Generic placeholder image

Current Organocatalysis

Editor-in-Chief

ISSN (Print): 2213-3372
ISSN (Online): 2213-3380

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Opinion Article

Potential uses of Topical Resiquimod for Mycosis Fungoides Tumor Stage

Author(s): Alberto Boretti*

Volume 11, Issue 1, 2024

Published on: 12 September, 2023

Page: [2 - 6] Pages: 5

DOI: 10.2174/2213337210666230731162414

Price: $65

Abstract

Introduction: Resiquimod (formula C17H22N4O2, ChEMBL Id 383322) is an immune response modifier that stimulates immune responses to tumor lesions mostly through toll-like receptors (TLR) 7 and 8 dependent pathways.

Methods: This study considers the potential use of Resiquimod in the topical treatment of mycosis fungoides tumor stage, for which standard-of-care is radiation therapy which has a very wellknown dosage-effects relationship and efficacy, but also side effects, and also the limitation regarding the number of times a same area can be treated during a lifetime.

Results: Trials are suggested to evaluate the use of Resiquimod as a replacement for radiation therapy in case of shallow lesions, as well as a supporting agent to increase the efficacy and reduce the dosage of the radiation therapy, lessening the side effects, and permitting many more uses for a same treatment zone.

Conclusion: This study proposes more research for the possible use of Resiquimod in the standalone or synergetic treatment of MF tumor phase, as there is potential, but not yet evidence, for these uses.

Keywords: Oncology, resiquimod, mycosis fungoides, radiation therapy, synergy, tumor.

« Previous Next »
Graphical Abstract

[1]
Discover how academic researchers use drugbank data. Available from: go.drugbank.com/drugs/DB06530
[2]
Your guide to quality drug data. Available from: go.drugbank.com/drugs/DB00724
[3]
Szeimies, R.M.; Bichel, J.; Ortonne, J.P.; Stockfleth, E.; Lee, J.; Meng, T-C. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br. J. Dermatol., 2008, 159(1), 205-210.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08615.x] [PMID: 18476957]
[4]
Fife, K.H.; Meng, T.C.; Ferris, D.G.; Liu, P. Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. Antimicrob. Agents Chemother., 2008, 52(2), 477-482.
[http://dx.doi.org/10.1128/AAC.01173-07] [PMID: 18039918]
[5]
Wu, J.; Huang, D.; Tyring, S. Resiquimod: A new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res., 2004, 64(2), 79-83.
[http://dx.doi.org/10.1016/j.antiviral.2004.07.002] [PMID: 15498602]
[6]
Tomai, M.A.; Miller, R.L.; Lipson, K.E.; Kieper, W.C.; Zarraga, I.E.; Vasilakos, J.P. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines, 2007, 6(5), 835-847.
[http://dx.doi.org/10.1586/14760584.6.5.835] [PMID: 17931162]
[7]
Rodell, C.B.; Arlauckas, S.P.; Cuccarese, M.F.; Garris, C.S.; Li, R.; Ahmed, M.S.; Kohler, R.H.; Pittet, M.J.; Weissleder, R. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng., 2018, 2(8), 578-588.
[http://dx.doi.org/10.1038/s41551-018-0236-8] [PMID: 31015631]
[8]
Hurst, J.; Prinz, N.; Lorenz, M.; Bauer, S.; Chapman, J.; Lackner, K.J.; von Landenberg, P. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1β and caspase-1 in monocytes and dendritic cells. Immunobiology, 2009, 214(8), 683-691.
[http://dx.doi.org/10.1016/j.imbio.2008.12.003] [PMID: 19249118]
[9]
McGowan, D.C. Latest advances in small molecule TLR 7/8 agonist drug research. Curr. Top. Med. Chem., 2019, 19(24), 2228-2238.
[http://dx.doi.org/10.2174/1568026619666191009165418] [PMID: 31769363]
[10]
Berger, A. Science commentary: Th1 and Th2 responses: What are they? BMJ, 2000, 321(7258), 424.
[http://dx.doi.org/10.1136/bmj.321.7258.424] [PMID: 10938051]
[11]
Zagon, I.S.; Donahue, R.N.; Rogosnitzky, M.; Mclaughlin, P.J. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp. Biol. Med., 2008, 233(8), 968-979.
[http://dx.doi.org/10.3181/0802-RM-58] [PMID: 18480416]
[12]
Opioid growth factor.. Available from: www.cancer.gov/publications/dictionaries/cancer-drug/def/opioid-growth-factor
[13]
Chong, A.; Loo, W.J.; Banney, L.; Grant, J.W.; Norris, P.G. Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study. J. Dermatolog. Treat., 2004, 15(2), 118-119.
[http://dx.doi.org/10.1080/09546630310019373] [PMID: 15204164]
[14]
Chi, H.; Li, C.; Zhao, F.S.; Zhang, L.; Ng, T.B.; Jin, G.; Sha, O. Anti-tumor activity of toll-like receptor 7 agonists. Front. Pharmacol., 2017, 8, 304.
[http://dx.doi.org/10.3389/fphar.2017.00304] [PMID: 28620298]
[15]
Rook, A.H.; Gelfand, J.C.; Wysocka, M. Topical resiquimod can induce disease regression, eradicate malignant T cells and enhance T cell effector functions in cutaneous T cell lymphoma. Blood, 2015, 126(12), 1452-1461.
[http://dx.doi.org/10.1182/blood-2015-02-630335] [PMID: 26228486]
[16]
Rook, A.H.; Gelfand, J.M.; Wysocka, M.; Troxel, A.B.; Benoit, B.; Surber, C.; Elenitsas, R.; Buchanan, M.A.; Leahy, D.S.; Watanabe, R.; Kirsch, I.R.; Kim, E.J.; Clark, R.A. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood, 2015, 126(12), 1452-1461.
[http://dx.doi.org/10.1182/blood-2015-02-630335] [PMID: 26228486]
[17]
Public summary of opinion on orphan designation Resiquimod for the treatment of cutaneous T-cell lymphoma. 2016. Available from: www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2016/05/WC500207498.pdf
[18]
Lewis, D.J.; Byekova, Y.A.; Emge, D.A.; Duvic, M. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: A case series. J. Dermatolog. Treat., 2017, 28(6), 567-569.
[http://dx.doi.org/10.1080/09546634.2017.1294728] [PMID: 28635518]
[19]
Deeths, M.J.; Chapman, J.T.; Dellavalle, R.P.; Zeng, C.; Aeling, J.L. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J. Am. Acad. Dermatol., 2005, 52(2), 275-280.
[http://dx.doi.org/10.1016/j.jaad.2004.04.049] [PMID: 15692473]
[20]
Coors, E.A.; Schuler, G.; Von Den Driesch, P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur. J. Dermatol., 2006, 16(4), 391-393.
[PMID: 16935796]
[21]
Gordon, M.C.; Sluzevich, J.C.; Jambusaria-Pahlajani, A. Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod. JAAD Case Rep., 2015, 1(6), 348-350.
[http://dx.doi.org/10.1016/j.jdcr.2015.08.007] [PMID: 27051776]
[22]
Shalabi, D.; Vadalia, N.; Nikbakht, N. Revisiting imiquimod for treatment of folliculotropic mycosis fungoides: A case report and review of the literature. Dermatol. Ther., 2019, 9(4), 807-814.
[http://dx.doi.org/10.1007/s13555-019-00317-2] [PMID: 31407190]
[23]
Martínez-González, M.C.; Verea-Hernando, M.M.; Yebra-Pimentel, M.T.; Del Pozo, J.; Mazaira, M.; Fonseca, E. Imiquimod in mycosis fungoides. Eur. J. Dermatol., 2008, 18(2), 148-152.
[PMID: 18424373]
[24]
Berg, S.; Villasenor-Park, J.; Haun, P.; Kim, E.J. Multidisciplinary management of mycosis fungoides/Sézary syndrome. Curr. Hematol. Malig. Rep., 2017, 12(3), 234-243.
[http://dx.doi.org/10.1007/s11899-017-0387-9] [PMID: 28540671]
[25]
Wennberg, E.; Richards, P.Q.; Bain, P.A.; Huang, V.; Sullivan, S.D.; Maverakis, E.M.; Molina, G.E.; Peggy, A.W. Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, development and evaluation (GRADE) criteria: A systematic review. JAAD Int., 2021, 3, 26-41.
[http://dx.doi.org/10.1016/j.jdin.2021.01.002] [PMID: 34409369]
[26]
Lo Sicco, K.; Latkowski, J.A. Therapeutic update: Update on cutaneous and systemic therapy for primary cutaneous t cell lymphoma, mycosis fungoides. J. Drugs Dermatol., 2015, 14(12), 1381-1383.
[PMID: 26659928]
[27]
Hristov, A.C.; Tejasvi, T.; Wilcox, R.A. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management. Am. J. Hematol., 2019, 94(9), 1027-1041.
[http://dx.doi.org/10.1002/ajh.25577] [PMID: 31313347]
[28]
Hoppe, R.T.; Kim, Y.H.; Horwitz, S.; Zic, J.A.; Corona, R. Treatment of early stage (IA to IIA) mycosis fungoides; UpToDate: Waltham, MA, 2017.
[29]
Meyer, T.; Surber, C.; French, L.E.; Stockfleth, E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin. Investig. Drugs, 2013, 22(1), 149-159.
[http://dx.doi.org/10.1517/13543784.2013.749236] [PMID: 23205468]
[30]
Schön, M.P.; Schön, M. Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. Apoptosis, 2004, 9(3), 291-298.
[http://dx.doi.org/10.1023/B:APPT.0000025805.55340.c3] [PMID: 15258460]
[31]
Kim, E.J.; Hess, S.; Richardson, S.K.; Newton, S.; Showe, L.C.; Benoit, B.M.; Ubriani, R.; Vittorio, C.C.; Junkins-Hopkins, J.M.; Wysocka, M.; Rook, A.H. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest., 2005, 115(4), 798-812.
[http://dx.doi.org/10.1172/JCI24826] [PMID: 15841167]
[32]
Hoppe, R.T. Mycosis fungoides: Radiation therapy. Dermatol. Ther., 2003, 16(4), 347-354.
[http://dx.doi.org/10.1111/j.1396-0296.2003.01647.x] [PMID: 14686978]
[33]
Ysebaert, L.; Truc, G.; Dalac, S.; Lambert, D.; Petrella, T.; Barillot, I.; Naudy, S.; Horiot, J-C.; Maingon, P. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int. J. Radiat. Oncol. Biol. Phys., 2004, 58(4), 1128-1134.
[http://dx.doi.org/10.1016/j.ijrobp.2003.08.007] [PMID: 15001254]
[34]
Morris, S.; Scarisbrick, J.; Frew, J.; Irwin, C.; Grieve, R.; Humber, C.; Kuciejewska, A.; Bayne, S.; Weatherhead, S.; Child, F.; Wain, M.; Whittaker, S. The results of low-dose total skin electron beam radiation therapy (TSEB) in patients with mycosis fungoides from the UK Cutaneous Lymphoma Group. Int. J. Radiat. Oncol. Biol. Phys., 2017, 99(3), 627-633.
[http://dx.doi.org/10.1016/j.ijrobp.2017.05.052] [PMID: 28843374]
[35]
Vonderheid, E.C.; Van Scott, E.J.; Wallner, P.E.; Johnson, W.C. A 10-year experience with topical mechlorethamine for mycosis fungoides: Comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat. Rep., 1979, 63(4), 681-689.
[PMID: 109206]
[36]
Gianfaldoni, S.; Gianfaldoni, R.; Wollina, U.; Lotti, J.; Tchernev, G.; Lotti, T. An overview on radiotherapy: From its history to its current applications in dermatology. Open Access Maced. J. Med. Sci., 2017, 5(4), 521-525.
[http://dx.doi.org/10.3889/oamjms.2017.122] [PMID: 28785349]
[37]
Nguyen, A.L.; Chong, E.G.; Lee, J.; Mirshahidi, S.; Mirshahidi, H. A case report of imiquimod topical therapy as treatment for cutaneous metastasis of breast cancer. Rare Tumors, 2021, 13, 2036361320975748.
[http://dx.doi.org/10.1177/2036361320975748] [PMID: 34249290]
[38]
Demaria, S.; Vanpouille-Box, C.; Formenti, S.C.; Adams, S. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. OncoImmunology, 2013, 2(10), e25997.
[http://dx.doi.org/10.4161/onci.25997] [PMID: 24404422]
[39]
Vatner, R.; Demaria, S.; Fenton-Kerimian, M.; Novik, Y.; Oratz, R.; Tiersten, A.; Goldberg, J.D.; Adams, S.; Formenti, S. Novel combination of Toll-Like Receptor (TLR)-7 agonist Imiquimod and local radiation therapy in the treatment of metastatic breast cancer involving the skin or chest wall. Int. J. Radiat. Oncol. Biol. Phys., 2013, 87(2), S111.
[http://dx.doi.org/10.1016/j.ijrobp.2013.06.286]
[40]
Aliru, M.L.; Schoenhals, J.E.; Venkatesulu, B.P.; Anderson, C.C.; Barsoumian, H.B.; Younes, A.I.; K Mahadevan, L.S.; Soeung, M.; Aziz, K.E.; Welsh, J.W.; Krishnan, S. Radiation therapy and immunotherapy: What is the optimal timing or sequencing? Immunotherapy, 2018, 10(4), 299-316.
[http://dx.doi.org/10.2217/imt-2017-0082] [PMID: 29421979]

Rights & Permissions Print Cite
Article Metrics
7
2
© 2024 Bentham Science Publishers | Privacy Policy